#United States #Ann Arbor #Micromedex #DynaMedex #Merge

Merge and Micromedex Recognized for Healthcare Excellence

On February 4, 2026, KLAS Research announced its prestigious Best in KLAS 2026 report, highlighting the exceptional work of Merge and Micromedex. This recognition marks a significant achievement for both organizations, reaffirming their dedication to enhancing healthcare delivery through innovative solutions.

Merge Hemo Leads in Cardiology Hemodynamics
For the 14th consecutive year, Merge Hemo has ranked as the leading choice for cardiology hemodynamics. This unwavering recognition showcases the platform's role in providing clinicians with timely and accurate data, enhancing patient care in critical areas of cardiovascular health. In addition to this accolade, Merge Cardio also made a notable appearance in the top three rankings for cardiology, achieving this commendable status for the 11th time.

Micromedex Excels in Clinical Decision Support
Micromedex, recognized for its clinical decision support capabilities, earned the Best in KLAS title for point-of-care drug reference for the second time. This accolade underscores its reliability as a trusted resource for healthcare professionals seeking evidence-based information at the moment of care. Additionally, the joint solution DynaMedex, in collaboration with EBSCO, celebrated its first number one ranking for clinical decision support in point-of-care disease reference.

The impressive rankings for Merge and Micromedex illustrate a robust ecosystem that empowers healthcare organizations across various specialties, including cardiology, radiology, and enterprise imaging. Their combined solutions are strategically designed to foster clinical excellence, facilitate workflow improvement, and ultimately enhance patient safety.

A Collaborative Commitment to Innovation
Ashish Sant, Executive Vice President and General Manager for Merge, highlights the dedication of his team: "Our ongoing collaboration with clients has been central to our success in delivering solutions that simplify workflows and improve patient outcomes." This perspective is echoed by Sonika Mathur, Executive Vice President for Micromedex, who comments on the transformative impact of the newly introduced homepage and AI-driven search functionalities, which have resonated well with users, as demonstrated by client feedback from KLAS Research.

KLAS: A Catalyst for Healthcare Improvement
KLAS Research plays a pivotal role in gathering insights from healthcare professionals regarding various software, services, and medical equipment. Their commitment to ensuring that provider voices are heard drives positive change within the industry. The data collected by KLAS is impartial and accurate, reflecting the genuine sentiments of healthcare workers and serving as a catalyst for enhancing vendor performance and patient care.

Looking Ahead
As Merge and Micromedex continue to innovate and improve their offerings, their focus remains on creating solutions that meet the complex needs of today’s healthcare landscape. With a presence in over 80 countries and a reputation for excellence, these organizations strive to ensure that clinicians worldwide have access to reliable and impactful information.

For more information about Merge, visit merative.com/merge, and learn more about Micromedex at merative.com/clinical-decision-support/micromedex.

Conclusion
The recognition received in the KLAS 2026 report is not just an accolade for Merge and Micromedex; it is a testament to their commitment to driving innovation in healthcare. By prioritizing clinical excellence and collaboration, these companies are poised to keep making waves in the healthcare industry, ensuring that improving patient outcomes is always at the forefront of their mission.